Alzheimer’s disease (AD) is a neurodegenerative disorder lacking early biochemical diagnosis and treatment. Lipids have been implicated in neurodegenerative disorders including AD. A shotgun lipidomic approach was undertaken to determine if lipid biomarkers exist that can discriminate AD cases from controls. The discovery study involved sera from 29 different stage AD cases and 32 controls. Lipid extraction was performed using organic solvent and the samples were directly infused into a time-of-flight mass spectrometer. Differences between AD cases and controls were detected with 87 statistically significant lipid candidate markers found. These potential lipid markers were reevaluated in a second confirmatory study involving 27 cases and 30 controls. Of the 87 candidates from the first study, 35 continued to be statistically significant in the second confirmatory set. Tandem MS studies were performed and almost all confirmed markers were characterized and classified. Using a Bayesian lasso probit regression model on the confirmed markers, a multi-marker set with AUC = 0.886 was developed comparing all stages of AD with controls. Additionally, using confirmed biomarkers, multi-marker sets with AUCs >0.90 were developed for each specific AD Clinical Dementia Rating versus controls, including the earliest stage of AD. More conservative and likely more realistic statistical analyses still found multi-marker sets that appeared useful in diagnosing AD. Finally, using ordinal modeling a set of markers was developed that staged AD accurately 70% of the time, p = 0.0079. These results suggest that these serum lipidomic biomarkers may help diagnose and perhaps even stage AD.
SchneiderJA, AggarwalNT, BarnesL, BoyleP, BennettDA (2009) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis18, 691.
2.
SchneiderJA, ArvanitakisZ, BangW, BennettDA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology69, 2197–2204.
3.
FerriCP, PrinceM, BrayneC, BrodatyH, FratiglioniL, GanguliM, HallK, HasegawaK, HendrieH, HuangY, JormA, MathersC, MenezesPR, RimmerE, ScazufcaM (2006) Global prevalence of dementia: A Delphi consensus study. Lancet366, 2112–2117.
4.
HardyJ (2009) The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal. J Neurochem110, 1129–1134.
MaccioniRB, MuñozJP, BarbeitoL (2001) The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Arch Med Res32, 367–381.
7.
JackC, PetersenRC, XuYC, O’BrienPC, SmithGE, IvnikRJ, BoeveBF, WaringSC, TangalosEG, KokmenE (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology52, 1397–1397.
8.
SamurakiM, MatsunariI, ChenW-P, YajimaK, YanaseD, FujikawaA, TakedaN, NishimuraS, MatsudaH, YamadaM (2007) Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer’s disease. Eur J Nucl Med Mol Imaging34, 1658–1669.
9.
HampelH, BürgerK, TeipelSJ, BokdeAL, ZetterbergH, BlennowK (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement4, 38–48.
10.
JackCR, LoweVJ, SenjemML, WeigandSD, KempBJ, ShiungMM, KnopmanDS, BoeveBF, KlunkWE, MathisCA, PetersenRC (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain131, 665–680.
11.
ForsbergA, EnglerH, AlmkvistO, BlomquistG, HagmanG, WallA, RingheimA, LångströmB, NordbergA (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging29, 1456–1465.
12.
JonassonM, WallA, ChiotisK, Saint-AubertL, WilkingH, SprychaM, BorgB, ThibblinA, ErikssonJ, SörensenJ, AntoniG, NordbergA, LubberinkM (2016) Tracer kinetic analysis of (S)-18F-THK5117 as a PET tracer for assessing tau pathology. J Nucl Med57, 574–581.
13.
PanegyresPK, RogersJM, McCarthyM, CampbellA, WuJS (2009) Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: A prospective, community-based study. BMC Neurol9, 41.
14.
TangBL, KumarR (2008) Biomarkers of mild cognitive impairment and Alzheimer’s disease. Ann Acad Med Singapore37, 406–405.
15.
MayeuxR, HonigL, TangM-X, ManlyJ, SternY, SchupfN, MehtaP (2003) Plasma Aβ40 and Aβ42 and Alzheimer’s disease Relation to age, mortality, and risk. Neurology61, 1185–1190.
16.
FukumotoH, TennisM, LocascioJJ, HymanBT, GrowdonJH, IrizarryMC (2003) Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch Neurol60, 958–964.
17.
IrizarryMC (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx1, 226–234.
18.
PattersonC, FeightnerJW, GarciaA, HsiungG-YR, MacKnightC, SadovnickAD (2008) Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Can Med Assoc J178, 548–556.
19.
WatsonAD (2006) Thematic review series: Systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: A global approach to lipid analysis in biological systems. J Lipid Res47, 2101–2111.
20.
KleinJ (2000) Membrane breakdown in acute and chronic neurodegeneration: Focus on choline-containing phospholipids. J Neural Transm107, 1027–1063.
21.
HuangX, MoirRD, TanziRE, BushAI, RogersJT (2004) Redox-active metals, oxidative stress, and Alzheimer’s disease pathology. Ann NY Acad Sci1012, 153–163.
22.
ButterfieldDA, PerluigiM, SultanaR (2006) Oxidative stress in Alzheimer’s disease brain: New insights from redox proteomics. Eur J Pharmacol545, 39–50.
23.
PraticòD (2010) The neurobiology of isoprostanes and Alzheimer’s disease. Biochim Biophys Acta1801, 930–933.
24.
BetL, CalabreseE, BavaL, MagniE, RapuzziS, PezzoliG, MarianiC (1999) Malondialdheyde production features in platelets of Parkinson and Alzheimer patients and in physiological aging. Neurosci Res Commun25, 33–41.
25.
SvennerholmL, GottfriesCG (1994) Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem62, 1039–1047.
26.
HanX, HoltzmanDM, McKeelDW, KelleyJ, MorrisJC (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: Potential role in disease pathogenesis. J Neurochem82, 809–818.
27.
CutlerRG, KellyJ, StorieK, PedersenWA, TammaraA, HatanpaaK, TroncosoJC, MattsonMP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A101, 2070–2075.
FiandacaMS, ZhongX, CheemaAK, OrquizaMH, ChidambaramS, TanMT, GresenzCR, FitzGeraldKT, NallsMA, SingletonAB, MapstoneM, FederoffHJ (2015) Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer’s disease. Front Neurol6, 237.
30.
HaraA, RadinNS (1978) Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem90, 420–426.
31.
AnandS, YoungSA, EsplinMS, PeadenB, TolleyHD, PorterTF, VarnerMW, D’AltonME, JacksonBJ, GravesSW (2016) Detection and confirmation of serum lipid biomarkers for preeclampsia using direct infusion mass spectrometry. J Lipid Res57, 687–696.
32.
van BuurenS, Groothuis-OudshoornK (2011) MICD: Multivariate imputation by chained equations in R. J Stat Software45, 1–67.
33.
ParkT, CasellaG (2008) The Bayesian lasso. J Amer Stat Assoc103, 681–686.
34.
TouboulD, RoyS, GermainDP, ChaminadeP, BrunelleA, LaprévoteO (2007) MALDI-TOF and cluster-TOF-SIMS imaging of Fabry disease biomarkers. Intl J Mass Spectrom260, 158–165.
35.
ChughtaiK, JiangL, GreenwoodTR, GlundeK, HeerenRM (2013) Mass spectrometry images acylcarnitines, phosphatidylcholines, and sphingomyelin in MDA-MB-231 breast tumor models. J Lipid Res54, 333–344.
36.
HsuF-F, TurkJ (2009) Electrospray ionization with low-energy collisionally activated dissociation tandem mass spectrometry of glycerophospholipids: Mechanisms of fragmentation and structural characterization. J Chromatogr B877, 2673–2695.
37.
EnomotoH, SugiuraY, SetouM, ZaimaN (2011) Visualization of phosphatidylcholine, lysophosphatidylcholine and sphingomyelin in mouse tongue body by matrix-assisted laser desorption/ionization imaging mass spectrometry. Anal Bioanal Chem400, 1913–1921.
38.
LiebischG, BinderM, SchiffererR, LangmannT, SchulzB, SchmitzG (2006) High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim Biophys Acta1761, 121–128.
39.
YuS, DongJ, ZhouW, RuiyueY, HongxiaL, HaijianZ, TianjiaoZ, HanbangG, ShuW, ChuanbaoZ, WenxiangC (2014) A rapid and precise method for quantification of fatty acids in human serum cholesteryl esters by liquid chromatography and tandem mass spectrometry. J Chromatogr B960, 222–229.
40.
BerryKAZ, MurphyRC (2004) Electrospray ionization tandem mass spectrometry of glycerophosphoethanolamine plasmalogen phospholipids. J Amer Soc Mass Spectrom15, 1499–1508.
41.
UchikataT, MatsubaraA, NishiumiS, YoshidaM, FukusakiE, BambaT (2012) Development of oxidized phosphatidylcholine isomer profiling method using supercritical fluid chromatography/tandem mass spectrometry. J Chromatogr A1250, 205–211.
42.
ByrdwellW, NeffWE (2002) Dual parallel electrospray ionization and atmospheric pressure chemical ionization mass spectrometry (MS), MS/MS and MS/MS/MS for the analysis of triacylglycerols and triacylglycerol oxidation products. Rapid Commun Mass Spectrom16, 300–319.
43.
ZebA (2012) Triacylglycerols composition, oxidation and oxidation compounds in camellia oil using liquid chromatography–mass spectrometry. Chem Phys Lipids165, 608–614.
WenkMR (2005) The emerging field of lipidomics. Nat Rev Drug Discov4, 594–610.
46.
HuC, van der HeijdenR, WangM, van der GreefJ, HankemeierT, XuG (2009) Analytical strategies in lipidomics and applications in disease biomarker discovery. J Chromatogr B877, 2836–2846.
47.
HanX, GrossRW (2005) Shotgun lipidomics: Electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev24, 367–412.
48.
MangialascheF, KivipeltoM, MecocciP, RizzutoD, PalmerK, WinbladB, FratiglioniL (2010) High plasma levels of vitamin E forms and reduced Alzheimer’s disease risk in advanced age. J Alzheimers Dis20, 1029.
49.
KontushA, SchekatolinaS (2004) Vitamin E in neurodegenerative disorders: Alzheimer’s disease. Ann NY Acad Sci1031, 249–262.
50.
BazanNG, de TurcoEBR, AllanG (1995) Mediators of injury in neurotrauma: Intracellular signal transduction and gene expression. J Neurotrauma12, 791–814.
IchiI, NakaharaK, MiyashitaY, HidakaA, KutsukakeS, InoueK, MaruyamaT, MiwaY, Harada-ShibaM, TsushimaM, KojoS (2006) Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids41, 859–863.
56.
RodríguezJJ, JonesVC, VerkhratskyA (2009) Impaired cell proliferation in the subventricular zone in an Alzheimer’s disease model. Neuroreport20, 907–912.
57.
CasserlyI, TopolEJ (2004) Convergence of atherosclerosis and Alzheimer’s disease: Inflammation, cholesterol, and misfolded proteins. Lancet363, 1139–1146.
58.
HanX, HoltzmanDM, McKeelDW (2001) Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J Neurochem77, 1168–1180.
59.
GinsbergL, RafiqueS, XuerebJH, RapoportSI, GershfeldNL (1995) Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res698, 223–226.
TerryRD, MasliahE, SalmonDP, ButtersN, DeTeresaR, HillR, HansenLA, KatzmanR (1991) Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol30, 572–580.
SultanaR, MecocciP, MangialascheF, CecchettiR, BaglioniM, ButterfieldDA (2010) Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer’s disease: Insights into the role of oxidative stress in Alzheimer’s disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis24, 77–84.
64.
SongF, PoljakA, SmytheGA, SachdevP (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer’s disease. Brain Res Rev61, 69–80.
65.
BurgessBL, McIsaacSA, NausKE, ChanJY, TansleyGHK, YangJ, MiaoF, RossCJD, van EckM, HaydenMR, van NostrandW, St George-HyslopP, WestawayD, WellingtonCL (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer’s disease mouse models with abundant Aβ in plasma. Neurobiol Dis24, 114–127.
